F. P. Manghi

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

J. Rosenstock, R. Heine, S. Kahn, 2021, The Lancet.

EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.

J. Davidson, B. Linetzky, M. Yu, 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

E. Ravussin, S. Klein, C. Ukomadu, 2022, Nature Network Boston.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Diane M. Miller, Natalia E. Shilkina, M. C. Cantero, 2018, Lancet.

84-LB: Efficacy and Safety of Tirzepatide vs. Semaglutide Once-Weekly as Add-On Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2)

J. Rosenstock, M. Davies, J. Frias, 2021, Diabetes.

Tirzepatide Once Weekly for the Treatment of Obesity.

L. Aronne, I. Lee, J. Ard, 2022, The New England journal of medicine.

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

I. Lee, J. Ard, J. Rosenstock, 2023, The Lancet.

A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8)

Honghua H. Jiang, J. Fahrbach, K. Dungan, 2016, Diabetes, obesity & metabolism.